Introduction
Migraine is a common primary headache disorder with a high prevalence and high socio-economic and personal impact; it is now ranked by the World Health Organization as the 20th leading cause of years of life lost to disability at the global level, and the 9th leading cause of disability in women (1) . In Japan, its prevalence is estimated at 8.4% of the general population (2) . (3) , several randomized control trials have been conducted (4) (5) (6) . BoNT-A treatment has already been used as migraine prevention in Europe and in the United States, however, no prospective study has been conducted yet in Japan, and the treatment is not approved in Japan.
Acute migraine treatment has dramatically changed after the introduction of a novel class of agents, selective 5-HT1B/1D/1F receptor agonists, known as triptans, which are highly efficacious and have a relatively safe profile, but the prophylactic treatment remains limited. Since the first report on the efficacy of treatment with botulinum toxin type A (BoNT-A)
The aim of this study was to evaluate the efficacy and tolerability of BoNT-A treatment for migraine prophylaxis in the Japanese population. F i g u r e 1 . Ch a n g e s i n MI DAS s c o r e f o l l o wi n g s i n g l e i n j e c t i o n ( N = 1 4 ) . Me a n MI DAS s c o r e d e c r e a s e d t wo mo n t h s a f t e r t h e s i n g l e i n j e c t i o n , b u t s t a t i s t i c a l s i g n i f i c a n c e wa s o n l y s e e n a t t wo mo n t h s a f t e r i n j e c t i o n ( P < 0 . 0 5 , 2 0 . 3 v s . 1 2 . 5 ) . 
T a b l e 1 . Re s u l t s o f S i n g l e I n j e c t i o n S t u d y
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Five patients were excluded from the primary analysis of this study because four patients were subsequently found to have medication overuse headache (9) , and one other patient was unable to stop preventive medicines, thus, a total of 14 patients completed this study and were analyzed for the single injection study. One of seven patients, who received re-
F i g u r e 2 . Ch a n g e s i n t h e f r e q u e n c y o f s e v e r e mi g r a i n e a t t a c k s f o l l o wi n g s i n g l e i n j e c t i o n ( N = 7 ) . Me a n n u mb e r o f s e v e r e mi g r a i n e a t t a c k s d e c r e a s e d f o l l o wi n g t h e s i n g l e i n j e c t i o n , b u t s t a t i s t i c a l s i g n i f i c a n c e wa s s e e n s e c o n d a n d t h i r d mo n t h s a f t e r t h e i n j e c t i o n ( P < 0 . 0 5 ) .
F i g u r e 3 . Re s u l t s o f mi g r a i n e q u e s t i o n n a i r e a b o u t c l i n i c a l e f f e c t s o f s i n g l e i n j e c t i o n o n h e a d a c h e d i s a b i l i t y . T h i r t e e n o f 1 4 p a t i e n t s s t a t e d mo d e r a t e o r ma r k e d i mp r o v e me n t s f o l l o wi n g t h e s i n g l e i n j e c t i o n ( F i g . 3 A) .
No p a t i e n t c o mp l a i n e d o f wo r s e n i n g o f h e a d a c h e . I n t e r ms o f c h a r a c t e r i s t i c s o f h e a d a c h e i mp r o v e me n t , mo s t p a t i e n t s s t a t e d r e d u c t i o n i n p a i n i n t e n s i t y , f o l l o we d b y r e d u c t i o n i n h e a d a c h e f r e q u e n c y a n d a me l i o r a t i o n o f a c c o mp a n y i n g s y mp t o ms i n c l u d i n g a l l o d y n i a a n d d r u g r e s p o n s i v e n e s s ( F i g . 3 B ) .
F i g u r e 4 . Ch a n g e s i n MI DAS s c o r e f o l l o wi n g r e p e a t e d i n j e c t i o n s ( N = 6 ) . Me a n MI DAS s c o r e d e c r e a s e d a f t e r t h e f i r s t i n j e c t i o n , b u t s t a t i s t i c a l s i g n i f i c a n t r e d u c t i o n wa s s e e n a t t h r e e mo n t h s a f t e r t h e s e c o n d i n j e c t i o n , a n d t wo a n d t h r e e mo n t h s a f t e r t h e t h i r d i n j e c t i o n s ( P < 0 . 0 5 ) .
peated injection, was also excluded from the analysis because of the presence of medication overuse headache. Only six patients were analyzed for repeated injection study.
In the single injection study, the mean MIDAS score decreased from the 20.4 score before the treatment to 12.5 at two months after the BoNT-A injection and 12.6 at three months after the injection, but statistical significance was only seen two months after the injection (P<0.05, Fig. 1) . Although the total number of migraine attacks did not change before and after treatment (Table 1) , the number of severe migraine attacks was significantly reduced two and three months after injection (Fig. 2) (Fig. 3) .
. The amount of analgesics consumption did not change after the injection (Table 1). Migraine questionnaire also showed global subjective improvement following the injection in several headache disability-related items, such as pain intensity, headache frequency, allodynia, and drug responsiveness on each migraine attack
In the repeated injections study, significant reduction was seen in the MIDAS score three months after the second and the third injection (Fig. 4) . The mean number of migraine attacks did not show a statistically significant reduction, but it tended to decrease two and three months after the second injection and two months after the third injection (P<0.10, Fig. 5 ). The number of severe migraine attacks also decreased following repeated injections but statistical analysis was not performed because only three of six patients had se- t h e f o r e h e a d , a n d s u b j e c t i v e e y e l i d d r o o p i n g , b u t n o s e r i o u s a d v e r s e e v e n t wa s o b s e r v e d . 
F i g u r e 5 . Ch a n g e s i n n u mb e r o f mi g r a i n e a t t a c k s f o l l o wi n g r e p e a t e d i n j e c t i o n s ( N = 6 ) . Me a n n u mb e r o f mi g r a i n e a t t a c k s d e c r e a s e d d u r i n g t wo a n d t h r e e mo n t h s a f t e r t h e s e c o n d i n j e c t i o n a n d t wo mo n t h s a f t e r t h e t h i r d i n j e c t i o n , b u t n o s t a t i s t i c a l s i g n i f i c a n c e wa s s e e n .
F i g u r e 6 . Ad v e r s e e v e n t s ( N= 1 4 ) . Re p o r t e d a d v e r s e e v e n t s a r e s h o wn i n F i g . 6 . S o me p a t i e n t s c o mp l a i n e d o f t r a n s i e n t d i s c o mf o r t s r e l a t e d t o i n j e c t i o n , s u c h a s l o c a l p a i n , f e e l i n g o f t h e s t r e t c h i n
vere migraine attacks before baseline periods of time (not shown). The amount of analgesics consumption did not change after repeated injections (not shown).
Regarding the adverse effect, several transient discomforts related to injection, such as feeling of stretched skin around the forehead or subjective eyelid drooping were reported, but no serious adverse event was observed (Fig. 6) . 
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